IP Library Granted Patent US 8,710,015
Granted Patent B2
US 8,710,015 · App. 13/365,446 · Granted Apr 29, 2014

Tropoelastin derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,710,015
App. No.
13/365,446
Granted
Apr 29, 2014
Kind
B2
Abstract

The invention relates to derivatives of tropoelastin and variants of those derivatives. The invention further provides expression products and hybrid molecules of the derivatives and variants of the invention. The invention further provides methods for the production of the derivatives, variants, expression products and hybrid molecules. Further provided are formulations, cross-linked structures and implants comprising the derivatives, variants, expression products and hybrid molecules of the invention. Further provided are uses of the derivatives, variants, expression products and hybrid molecules of the invention.

Claims (7)

1. A method for forming an implant having a pre-defined glycosaminoglycan (GAG) binding activity comprising:

(a) selecting tropoelastin monomers;

(b) forming a composition with the selected monomers; and

(c) cross linking the monomers in the composition in the presence of a mould for forming an implant wherein an implant having GAG binding activity is formed when a tropoelastin monomer containing tropoelastin domain 26A is selected, thereby forming an implant having a pre-defined glycosaminoglycan (GAG) binding activity and wherein the implant comprises a tropoelastin selected from the group consisting of SHELδmodified (SEQ ID NO: 5), SHELgamma (SEQ ID NO: 9), SHEL31-36 (SEQ ID NO: 10), SHEL32-36 (SEQ ID NO: 11 and SHELδ26A SEQ ID NO: 3).

2. The method of claim 1 wherein the tropoelastin is cross-linked by cross-linking of lysine or glutamic acid side chains in tropoelastin.

3. The method of claim 1 wherein the mould takes the form of a flat surface for forming an implant into sheet form.

4. The method of claim 1 wherein the GAG binding activity of the cross-linked tropoelastin obtained from the composition is adjusted based on a comparison of a SHEL to SHELd26A amount in the composition.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: ELASTAGEN PTY LTD
To: ALLERGAN AUSTRALIA PTY LTD
Reel/Frame 048163/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: ALLERGAN AUSTRALIA PTY LTD
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 048164/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: THE UNIVERSITY OF SYDNEY
To: ELASTAGEN PTY LTD
Reel/Frame 042994/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2012
From: WEISS, ANTHONY S.
To: UNIVERSITY OF SYDNEY
Reel/Frame 027661/0811 →